Share Price:

APNASPENAspen Pharmacare Hldgs17099148 (0.87%)

Investor Relations

Investor Hub

We are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality, affordable medicines. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability.

Stephen Saad

Group Chief Executive

Our business strategy is to create value for our stakeholders by promoting access to medicines through building robust product portfolios that achieve organic growth and by leveraging our world-class manufacturing capacities and capabilities. We seek to achieve this by building a differentiated portfolio of relevant IP, creating value through our complex manufacturing capabilities and enabling access through our globally integrated supply chain.

Our market positioning is focused on opportunities presented by emerging markets, balanced with presence in more established, stable developed markets. Through our dynamic portfolio management model, we build, optimise and reshape our basket of products to achieve a global product portfolio of niche, specialty products complemented by leading regional brands, aligned to our manufacturing capability.

We have proven manufacturing capability and capacity, creating access and sustainability collaboration opportunities for multinationals.

Firm Analyst Contact Details

Covering analyst


Raj Sinha

Covering analyst


Letlotlo Lenake

Covering Analyst


Alex Comer

Covering analyst


Luyanda Njilo


Covering Analyst


Roy Campbell

Covering analyst

Standard Bank

Anuja Joshi


Latest Results: FY 2023

Revenue increased by 5%
(-3% CER) to
R 0 ,7 billion
June 2022: R38,6 billion
Normalised EBITDA increased by 1% (-6% CER) to
R 0 ,1 billion
June 2022: R11,0 billion
Headline earnings per share decreased by -4% (-11% in CER) to
1 0 cents
June 2022: 1 461,2 cents
Normalised headline earnings per share decreased by -8% (-15% CER) to
1 0 cents
June 2022: 1 627,6 cents
Dividend declared to shareholders increased by 5% to
0 cents per ordinary share

June 2022: 326 cents

Financial Results and Presentations

Annual Results

Interim Results

Additional Presentations and Webcasts

Integrated Reporting

Share Price Information

Financial Calendar

29th November 2023

Aspen NDB Site Visit and Manufacturing Day

Add To Calendar

6th December 2023

HSBC Africa Conference - The Vineyard Hotel, Newlands (6-8 December)

Add To Calendar

7th December 2023

Annual General Meeting

Add To Calendar

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.